Patents Examined by Quang Nguyen
  • Patent number: 8865881
    Abstract: Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: October 21, 2014
    Assignee: California Institute of Technology
    Inventors: Alejandro Benjamin Balazs, David Baltimore
  • Patent number: 8852928
    Abstract: The present invention relates generally to chemical-inducible system and to methods of use in transgenic animals. More specifically, the present invention relates to a chimeric transcription factor that binds to a ligand and functions in ligand-dependent manner to induce expression of genes of interest under the control of a synthetic operator-promoter sequence. The expression of genes of interest can be tightly controlled by adding or removing the ligand.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: October 7, 2014
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Alexander Emelyanov, Sergey Parinov, Nam-Hai Chua
  • Patent number: 8846387
    Abstract: This invention provides methods for obtaining targeted gene modification in vertebrate cells using parvoviral vectors, including adeno-associated virus (AAV). The parvoviral vectors used in the methods of the invention are capable of targeting a specific genetic modification to a preselected target locus in a cellular genome by homologous pairing.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: September 30, 2014
    Assignee: The University of Washington
    Inventors: David W. Russell, Roli K. Hirata
  • Patent number: 8822663
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 2, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Jason P. Schrum, Stéphane Bancel, Noubar B. Afeyan
  • Patent number: 8791247
    Abstract: Disclosed is an expression vector system for variants of coagulation factor VIII (FVIII) and von Willebrand factor (vWF). In detail, mutant vWF the size of which is significantly reduced by deleting exons but which has remarkably increased FVIII stabilizing and activating efficiency, and an expression vector system useful for the treatment of hemophilia which is capable of expressing the same along with FVIII are disclosed. Use of the mutant vWF with a reduced size enables effective expression of FVIII in a viral vector and significantly enhanced FVIII activity. Further, the viral vector may be effectively used to treat hemophilia through gene therapy.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: July 29, 2014
    Assignee: Korea University Industrial & Academic Collaboration Foundation
    Inventors: Sang Yun Choi, Sang Won Park
  • Patent number: 8772032
    Abstract: Disclosed herein are methods and materials for influencing proliferation of stem cells. Specifically exemplified herein are compositions comprising cerium oxide nanoparticles which can be used to stimulate proliferation of stem cells under common culture conditions, or which can be utilized to improve therapeutic outcomes.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: July 8, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Kiminohu Sugaya, Sudipta Seal
  • Patent number: 8765698
    Abstract: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: July 1, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Alexander M. Cole
  • Patent number: 8759088
    Abstract: The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: June 24, 2014
    Assignee: Actogenix N.V.
    Inventors: Lothar Steidler, Klaas Vandenbroucke, Sabine Neirynck
  • Patent number: 8742085
    Abstract: A method for preparing a transgenic animal of simultaneous multiple-gene expression is provided. Additionally, a method for preparing a transgenic embryo, which introduces both phytase gene and human myxovirus resistant gene A into a target embryo, to obtain a transgenic embryo is provided. The transgenic animal of simultaneous multiple-gene expression can be achieved by transplanting the transgenic embryo into the body of a female target animal. A significant advantage of the foregoing methods, among many others, exists in that the simultaneous expression of multiple genes can be achieved in one transgenosis, which provides a convenient method for the preparation of combined-gene transferred animals.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 3, 2014
    Assignee: Institute of Animal Science, Chinese Academy of Agricultural Sciences
    Inventors: Kui Li, Huiming Ju, Junhua Fan, Lijing Bai, Yulian Mu, Shulin Yang, Zhonglin Tang, Wentao Cui
  • Patent number: 8716447
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in in vivo and in vitro environments).
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 6, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Ofer Yizhar, Lisa Gunaydin, Peter Hegemann, Andre Berndt
  • Patent number: 8663971
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: March 4, 2014
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Patent number: 8632797
    Abstract: Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that can act as repair and remodeling factors. An exemplary method to modulate flexor tendon healing and provide elimination or reduction of fibrotic adhesions involves loading a freeze-dried flexor digitorum longus allograft with recombinant adeno-associated viral (rAAV) vectors for the targeted and transient expression of growth/differentiation factor 5 (GDF5).
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: January 21, 2014
    Assignee: University of Rochester
    Inventors: Hani A. Awad, Edward M. Schwarz
  • Patent number: 8628957
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 14, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Patent number: 8617534
    Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 31, 2013
    Assignee: San Diego State University (SDSU) Foundation
    Inventors: Mark A. Sussman, John A. Muraski
  • Patent number: 8597945
    Abstract: A method of differentiating embryonic stem cells into ventral spinal progenitor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox1?/Pax6+ in the presence of retinoic acid, wherein the cells express Hoxb4, but not Otx2 or Bf1.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: December 3, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xue-Jun Li
  • Patent number: 8598331
    Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: December 3, 2013
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra
  • Patent number: 8562968
    Abstract: The present invention relates to the use of a composition containing stem cells as well as CD6 depleted stem cells for the induction of a tolerance to allogenic transplants and/or for the treatment of blood, immune, and cancer diseases for time-staggered application wherein first the stem cells are applied followed by application of the CD6 depleted stem cells. Furthermore, the present invention relates to a compound preparation containing stem cells and CD6 depleted stem cells.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: October 22, 2013
    Assignee: GSF-Forshungszentrum für Umwelt und Gesundheit, GmbH
    Inventors: Wolfgang Günther, Hans Jochen Kolb
  • Patent number: 8557515
    Abstract: The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: October 15, 2013
    Assignee: Thomas Jefferson University
    Inventors: Carlo Croce, George Calin
  • Patent number: 8529885
    Abstract: The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in in vivo gene therapy.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: September 10, 2013
    Assignees: Academisch Medisch Centrum, Institut National de la Sante et de la Recherche Medicale
    Inventors: Paul Peter Tak, Christian Jorgensen
  • Patent number: 8486695
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 16, 2013
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy